Core Viewpoint - The stock of Giant Bio (02367) has declined nearly 4%, with a current price of HKD 36.82 and a trading volume of HKD 241 million, following a report from CMB International that downgraded revenue growth forecasts for 2025/26 due to short-term pressures on Comfy brand sales [1] Group 1: Company Performance - CMB International has revised the revenue growth forecast for Giant Bio to -3.5% and 13.6% for 2025/26, indicating a challenging sales environment during the "Double Eleven" shopping festival, primarily due to underperformance in the sales of the Comfy brand [1] - Management has adjusted the performance guidance for the year, expecting revenue to remain flat or slightly decline, and has lowered the net profit forecast to a mid-to-high single-digit percentage decline [1] Group 2: Sales Performance - During the "Double Eleven" period, sales of the Comfy brand on Tmall and Douyin saw a year-on-year decline of 20% and 50%, respectively, while the Collgene brand achieved positive growth during the same period [1] - The company is actively adjusting its channel strategy in response to competitive pressures in the industry, while maintaining strategic focus to enhance pricing and consumer experience, and increasing the proportion of self-broadcast channels to lay the foundation for long-term growth [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 53.89, down from a previous target of HKD 58.35, indicating a potential upside of 35.7% from the current price of HKD 39.70 [2][6]. Core Insights - The company's short-term performance is under pressure due to disappointing sales during the "Double Eleven" shopping festival, primarily attributed to the underperformance of the "Dabo" sales channel. This reflects both strategic channel adjustments by the company and overall competitive pressures in the industry [6]. - Management remains committed to maintaining pricing stability and enhancing consumer experience, which is expected to lay a foundation for long-term growth. The company plans to launch several key new products next year to drive a new growth cycle [6]. - The company has been approved to repurchase up to 104 million shares, representing 10% of its total share capital, demonstrating confidence in its long-term development [6]. Financial Summary - For FY23A, the company reported sales revenue of RMB 3,524 million, with a year-on-year growth of 49.0%. Projections for FY25E and FY26E show expected revenues of RMB 5,347 million and RMB 6,075 million, respectively, with growth rates of -3.5% and 13.6% [2][11]. - The net profit attributable to shareholders for FY23A was RMB 1,452 million, reflecting a year-on-year increase of 44.9%. The forecast for FY25E and FY26E is RMB 1,903 million and RMB 2,126 million, with growth rates of -7.7% and 11.7% [2][11]. - The company's price-to-earnings (P/E) ratio is projected to be 24.0 for FY23A, decreasing to 15.2 by FY27E, indicating a potential increase in valuation as earnings grow [2][11]. Sales Performance - During the "Double Eleven" event, the company's online GMV for "Kefumei" declined approximately 30% year-on-year, with Tmall GMV down about 20% due to the company's decision to avoid aggressive price wars. However, the self-operated and mid-tier influencer channels showed resilience [6]. - The "Keli Jin" brand experienced double-digit growth in online GMV during the same period, particularly strong in the Douyin channel, indicating a successful strategy in diversifying sales channels [6]. Product Strategy - The company is actively cultivating a second tier of products to optimize its product structure, with expectations for significant revenue growth from new product launches in 2025 and 2026 [6]. - The medical beauty product line is set to expand, with the first injectable recombinant collagen product approved and plans for rapid terminal coverage expansion in 2026, which is anticipated to become a significant growth driver with higher profit margins than cosmetics [6].